PREPARATION AND SOLID STATE CHARACTERIZATION OF NANOCRYSTALS FOR SOLUBILITY ENHANCEMENT OF QUETIAPINE FUMARATE
Objective: Quetiapine fumarate (QF) has poor water solubility and its oral bioavailability is observed to be 9% . The objective of the present work is to prepare QF nanoparticles by wet media milling (WMM) and explore on the improvement in solubility with the aim of dose reduction and minimizing the side effects associated with its oral administration.
Methods: Nanoparticle of QF were prepared by WMM using sodiumlaurylsulphate (SLS), polyvinylpyrrolidone (PVP), hydroxypropylcellulose (HPC) and Hydroxypropylmethylcellulose (HPMC) as surface stabilizers. The nanosuspensions obtained were characterized for its mean particle size (MPS), zeta-potential (ZP) and Polydispersity-index (PI). Further lyophilized nanoparticles were characterized for MPS, ZP, PI, saturation solubility (SS), X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC), Infra-Red (IR) and Scanning electron Microscopy (SEM).
Results: The MPS of the nanosuspensions obtained after 1 hour WMM and its lyophilized nanoparticlesis observed to be less than 1000 nm with PI ranges from 0.2 to 0.6 and negative ZP ranging from -30 to -36 mV. Lyophilized nanoparticles have shown significant improvement in SS when compared to plain drug. XRD and DSC have shown absence of the crystalline peaks and endotherm of QF respectively, indicating loss of its crystallinity. IR spectra showed no change in position of bands thus drug is compatible with surface stabilizers used. SEM photographs confirmed the formation of nanoparticles.
Conclusion: From the above results it has been concluded that by subjecting QF to WMM, QF nanoparticles were obtained with significant improvement in saturation solubility and drug losing its crystalline nature when compared to plain drug.
Keywords: Quetiapine Fumarate, Nanosuspension, Wet media milling, Lyophilized nanoparticles.
2. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorly-water soluble compounds using wet media milling technology.Advanced Drug Delivery Reviews2011;63(6):427-40
3. Haresh T, Nehal I, J. Mulani1, and In Vitro Evaluation of pH-Independent Sustained Release Drug Delivery System of Quetiapine Fumarate. International Journal of Pharmaceutical Innovations 2011;1(2):59-75.
4. Deecaraman M, Rani C. ArunkumarN, Nanosuspension technology and its applications in drug delivery. Asian Journal of Pharmaceutics 2009;3(3):168-73.
5. Lakshmi P, Ashwini KG. Nanosuspension technology:A review. Int J Pharm PharmSci,2010;2:35â€“40
6. Chris W. Harry The Challenges of Manufacturing Nanoparticles through Media Milling;Pharmatech Talk:Equipment and Processing Report. Advanced drug delivery reviews 2008.
7. Vermaa S, Lan Y, Gokhale R, Burgessa DJ, J. Quality by design approach to understand the process of nanosuspension preparation. Int 377 18598 2009:1-2.
8. Liversidge GG, Cundy KC, J. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs:Absolute oral bioavailability of nanocrystallinedanazol in beagle dogs. Int 1995;125:91-7.
9. Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm 1989;51:9-17.
10. Metallopolymer NanocompositesSpringer Series in Materials Science. Principles and Mechanisms of Nanoparticle Stabilization by Polymers 2005;81:65-113.
11. Nagavarma B, Hemant S, Ayaz A, Vasudha L, S. K, Shivakumar HG, et al. V N, Different techniques for preparation of polymeric nanoparticles-A review. Asian Clin Res 5 Suppl 3;2012:16-23.
12. W. B. N. Rasenack, Micron-size particles:common and novel micronization techniques. PharmDevTechnol 2004;9(1):1-13.
13. Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling:critical process parameters, particle fracturing and stabilization methods. The Journal of pharmacy and pharmacology 2010;62(11):1569-79.
14. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery:a perspective on formulating poorly-water soluble compounds using wet media milling technology. Advanced drug delivery reviews 2011;63(6):427-40.
15. Verma S, Lan Y, Gokhale R, Burgess DJ. Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm 2009;377(1-2):185-98.
16. Melkersson K, Dahl M-L. Adverse metabolic effects associated with atypical antipsychotics:literature review and clinical implications. Drugs 2004;64(7):701-23.
17. Langman LJ, Kaliciak HA, Carlyle S. Fatal overdoses associated with quetiapine. J Anal Toxicol 2004;28(6):520-5.
18. Vishal R, J. Patel and Y. K AgrawalNanosuspensionAn approach to enhance solubility of drugs Pharm Technol Res 2011;2(2):81-7.
19. Kumar AN, Deecaraman M, Rani C. Nanosuspension technology and its applications in drug delivery.Asian J Pharm. 2009;3:168-73
20. Chen Y, Liu J, Yang X, Zhao X, Xu H. Oleanolic acid nanosuspensions:preparation, in-vitro characterization and enhanced hepatoprotective effect. The Journal of pharmacy and pharmacology 2005;57(2):259-64.
21. Jacobs C, MÃ¼ller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 2002;19(2):189-94.
22. Yang JZ, Young AL, Chiang P-C, Thurston A, Pretzer DK. Fluticasone and budesonide nanosuspensions for pulmonary delivery:preparation, characterization, and pharmacokinetic studies. J Pharm Sci 2008;97(11):4869-78.
23. Liang YC, Binner JG. Effect of triblock copolymer non-ionic surfactants on the rheology of 3 mol% yttriastabilised zirconia nanosuspensions. Ceram Int 2008;34(2):293-7.
24. Muller RH, Grau MJ, World APV, Meeting A. Increase of dissolution rate and solubility of poorly water soluble drugs as nanosuspension. Proceedings Paris 1998;2:62-624.
25. Young TJ, Mawson S, Johnston KP, Henriksen IB, Pace GW, Mishra AK. Rapid expansion from supercritical to aqueous solution to produce submicron suspensions of water-insoluble drugs. Biotechnol Prog 2000;16(3):402-7.
26. H. A, Rainer H, J. Jens-Uwe and MÃ¼ller.Nanocrystal technology, drug delivery and clinical applications. Int 2008;3(3):295-310.
27. Kumar AN, Deecaraman M, Rani C. Nanosuspension technology and its applications in drug delivery.Asian J Pharma.2009;3:168-73.
28. Setler P, R. II. London. Identifying new oral technologies to meet your drug delivery needs for the delivery of peptides and proteins and poorly soluble molecules. Drug delivery system 1999.
29. Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm 2006;312(1-2):179-86.
30. Silverstein RM, Webster FX. Spectrometric Identification of Organic, Compounds, 6th ed, Jhon Wiley and Sons,;, p 72-1262002. 71-109.
31. AshutoshKar, Text book of Pharmaceutical Drug Analysis, 2nded, new Age International Publishers;;p2005. 293-311.
32. Jores K, Mehnert W, Drecusler M, Bunyes H, Johan C, Mader K, et al. Investigation on the stricter of solid lipid nanoparticles and oil-loaded solid nanoparticles by photon correlation spectroscopy, field flow fractionation and transmission electron microscopy. Release 2004;17:217-27.
33. SovanLal PK, Manna GP, Mohanta R, Utpal P. Manavalan. Journal of Applied Pharmaceutical Science. Advanced drug delivery reviews 2011;01(06):228-34.